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Background: Enterovirus-D68 (EV-D68) is a respiratory virus within 
the genus Enterovirus and the family of Picornaviridae. Genetically, it 
is closely related to rhinovirus that replicates in the respiratory tract and 
causes respiratory disease. Since 2014, EV-D68 has been associated with 
the neurologic syndrome of acute flaccid myelitis (AFM).
Methods: In October 2016, questionnaires were sent out to a European net-
work including 66 virologists and clinicians, to develop an inventory of EV-
D68–associated AFM cases in Europe. Clinical and virologic information 
of case patients was requested. In addition, epidemiologic information on 
EV testing was collected for the period between March and October 2016.
Results: Twenty-nine cases of EV-D68–associated AFM were identified, 
from 12 different European countries. Five originated from France, 5 from 
Scotland and 3 each from Sweden, Norway and Spain. Twenty-six were 
children (median age 3.8 years), 3 were adults. EV-D68 was detected in 
respiratory materials (n = 27), feces (n = 8) and/or cerebrospinal fluid (n 
= 2). Common clinical features were asymmetric flaccid limb weakness, 
cranial nerve deficits and bulbar symptoms. On magnetic resonance imag-
ing, typical findings were hyperintensity of the central cord and/or brain-
stem; low motor amplitudes with normal conduction velocities were seen 
on electromyography. Full clinical recovery was rare (n = 3), and 2 patients 
died. The epidemiologic data from 16 European laboratories showed that of 
all EV-D68–positive samples, 99% was detected in a respiratory specimen.
Conclusions: For 2016, 29 EV-D68–related AFM cases were identified in 
mostly Western Europe. This is likely an underestimation, because case iden-
tification is dependent on awareness among clinicians, adequate viral diag-
nostics on respiratory samples and the capability of laboratories to type EVs.
Key Words: paralysis, myelitis, enterovirus, enterovirus D68, laboratory 
surveillance
(Pediatr Infect Dis J 2019;38:16–21)
Enterovirus-D68 (EV-D68) is a member of the genus Entero-virus, which belongs to the Picornaviridae family. The genus 
Enterovirus consists of many species, including human EV-A, B, 
C, D and human rhinovirus A, B, C, which can be further classified 
in different genotypes. Examples of EV genotypes are coxsacki-
evirus, enterovirus A71, poliovirus and echovirus. These viruses 
are associated with a range of clinical symptoms, such as myocar-
ditis, hand–foot–mouth disease, acute flaccid paralysis (AFP) and 
aseptic meningitis. The majority of enteroviruses replicate in the 
gastrointestinal tract and can be detected in stool samples. EV-D68 
and rhinovirus, however, replicate in the upper airways and are best 
detected in respiratory samples.
Since 2014, EV-D68 has gained interest after causing a large 
respiratory disease outbreak in North America.1 Symptoms varied 
in severity from a common cold to respiratory failure requiring 
mechanical ventilation. Most hospitalized patients were children 
and severe cases often had underlying pulmonary conditions, such 
as asthma.2 The concurrent circulation of EV-D68 in Europe was 
shown by a joint effort of the European Society of Clinical Virol-
ogy (ESCV) – European Centre for Disease Prevention and Con-
trol (ECDC) EV-D68 study group: 16,332 respiratory samples were 
screened for EV-D68 and 343 (2.1%) were positive.3
During this 2014 epidemic, 120 cases of acute flaccid mye-
litis (AFM) in children were identified in the United States, with 
the most common virus detected in upper respiratory tract speci-
mens being EV-D68.4 AFM is a polio-like neurologic condition, 
characterized by an acute onset of asymmetric multifocal limb 
weakness with spinal cord lesions evident on magnetic resonance 
imaging (MRI).5 An epidemiologic link was made between the 
AFM upsurge and the concurrent EV-D68 outbreak in the United 
States.4,6 During the same period, 4 AFM patients with respiratory 
EV-D68 infections were reported in Europe.7–9
In the winter of 2015/2016, 2 AFM cases with concurrent 
EV-D68 infection were identified in Wales,10 and in July 2016, a 
severe case of EV-D68–related AFM in a 4-year-old boy was iden-
tified in the Netherlands.11 Subsequently, through an e-mail alert 
to the previously established ESCV-ECDC EV-D68 study group 
network, more cases of EV-D68–related AFM were rapidly iden-
tified. An intense collaboration between virologists and clinicians 
(ie, pediatric neurologists and infection disease specialists) from 
across Europe was established. In this article, we present the clini-
cal and virologic data of the 29 cases that were identified through 
this network, to illustrate the clinical picture and to improve future 
patient identification.
The 2014 ESCV-ECDC collaborative work3 showed that 
only limited data were available on the epidemiology of respiratory 
EV infections. This was especially, but not exclusively, the case for 
Eastern and Southern European countries, among others because 
of a lack of diagnostic testing and typing of EVs in respiratory 
samples. In line with our study in 2014, we collected epidemio-
logic data for Europe in 2016. We present data on EV and EV-D68 
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testing and positivity rates, to emphasize the impact of adequate 
diagnostics, and on notification regulations of AFM in the various 
European countries.
MATERIALS AND METHODS
Members of the 2014 ESCV-ECDC EV-D68 study group3, 
mostly virologists, were contacted by the coordinating center 
(University Medical Center, Groningen, The Netherlands) through 
an e-mail alert. Additionally, EV reference laboratories in Eastern 
Europe were informed of the initiative, as they were underrepre-
sented in the study group. Finally, through this network and in 
reply to scientific presentations or publications on the subject, 
we contacted clinicians who diagnosed or treated a patient with 
EV-D68–related AFM. The collaborating centers and clinicians 
(from this point on referred to as the 2016 EV-D68 AFM Working 
Group, with 66 members (Supplemental Digital Content 1, http://
links.lww.com/INF/D269) were sent a questionnaire by which 
they were asked to report the number of EV-D68–related AFM 
cases diagnosed in 2016. For each case, information was inquired 
regarding age, gender, prodromal phase, neurologic abnormali-
ties (mental status, signs of nuchal rigidity, cranial nerve dysfunc-
tion, limb weakness, tendon reflexes and sensory disturbances), 
virologic diagnostics, neurologic investigations [cerebrospinal 
fluid (CSF) analysis, MRI, electromyography (EMG)] and clini-
cal follow-up.
Additionally, information on diagnostic EV testing was col-
lected via the questionnaire. For the period between March and 
October 2016, we requested the number of EV tests performed 
on all clinical specimens (respiratory, CSF, feces and blood), the 
number of EV-positive tests and the number of EV-D68–positive 
tests. Twenty-one laboratories responded, including both diagnostic 
and reference laboratories. The national reference center of Bul-
garia reported that EV detection was performed in their institution, 
but no further typing was done for non-polio EVs. Furthermore, 
the data from 3 laboratories that tested less than 100 samples for 
EV (from Portugal, Czech and Finland) and from 1 laboratory that 
could not detect EV-D68 with the current techniques (from Esto-
nia) were excluded.
Finally, the notification status of AFM was questioned per 
country.
Case Definition EV-D68–related AFM
AFM is a specific form of AFP. Its definition was stated in 
2015 and adapted since by the Centers for Disease Control and 
Prevention.5 The 3 key components of the EV-D68–related AFM 
case definition are: (1) Acute onset of focal limb weakness, (2) 
MRI showing a spinal cord lesion largely restricted to the grey 
matter and spanning 1 or more spinal segments and (3) Detection 
of EV-D68 in a respiratory, fecal, blood or CSF specimen using a 
validated polymerase chain reaction (PCR) assay for EV-D68, or a 
validated PCR assay for EVs in general and subsequent sequenc-
ing and typing. If MRI is not performed, or findings are normal, 
and the CSF shows pleocytosis, the patient is considered a “prob-
able” case.
Typing and Phylogenetic Mapping
To compare the viral sequences, the collaborating centers 
were asked to share the sequencing files of their EV-D68 cases 
(both of respiratory and AFM cases). Alternatively, samples could 
be sent to one of the participating laboratories for sequencing. Typ-
ing was performed using the standard method described by Nix 
et al,12 which consists of partial sequencing of the viral protein 1. 
Phylogenetic analysis was performed using BioNumerics Software 
version 6.6 (Applied Maths, Sint-Martens-Latem, Belgium).
Ethics Approval
The research ethics committee of the coordinating center 
confirmed exemption from the Medical Research Involving Human 
Subjects Act (Decree M17.207412). Local ethics approval and 
informed consent from participating patients or their parents were 
obtained according to individual institutional requirements.
RESULTS
EV-D68–related AFM Cases
We received the clinical data from 29 EV-D68–related AFM 
cases, from 12 different countries. Table 1 shows the clinical data 
of these cases (more extensive descriptions can be found in the 
Table, Supplemental Digital Content 2, http://links.lww.com/INF/
D270). The distribution of cases over Europe is shown in the (Figure, 
Supplemental Digital Content 3, http://links.lww.com/INF/D271. 
Twenty-six children were affected, with a median age of 3.8 years 
(range 1.6–9.0) and 3 adults were included in this series. Gender was 
equally distributed. EV-D68 was detected in a respiratory sample of 
27 patients, in the feces of 8 patients and in the CSF of 2 patients. 
Only 1 child was coinfected with another neurotropic virus, EV-A71.
Medical history was nonsignificant, except for an adult 
patient who received an allogeneic hematopoietic stem cell trans-
plantation for Non-Hodgkin B-cell lymphoma 2 years earlier.13 A 
prodromal phase with fever (n = 24) and/or respiratory symptoms 
(n = 26) preceded weakness by a median period of 2 days. Weak-
ness was flaccid and usually asymmetric, with decreased or absent 
reflexes. Upper limbs were more frequently and often more severely 
affected than lower limbs. Cranial nerve deficits were common (n = 
17). Nineteen patients needed ventilatory support. Information on 
duration of ventilator dependency was scarce, but at least 7 children 
needed tracheostomy for long-term ventilator support.
CSF analysis frequently showed a moderate pleocytosis 
(normal value <5 leukocytes/µL), while protein levels were mostly 
normal or slightly raised (normal value <0.55 g/L, dependent on 
age and center).
MRI was reported to be abnormal in 25 cases, with hyper-
intensity in the central grey matter of the cervical and/or thoracic 
spine in 23 patients and hyperintensity of the dorsal brainstem in 
17 patients. Figure 1 shows the typical AFM lesions on MRI for 2 
patients. EMG was performed in 11 patients and generally revealed 
decreased amplitude of compound motor action potentials with 
normal conduction velocities and absence of conduction blocks, 
compatible with anterior horn cell disease. Spontaneous muscle 
fiber activity, either positive sharp waves or fibrillations, was found 
in the affected muscles when needle EMG was performed after suf-
ficient time (range: 7 days to 3 months).
Most patients were treated with intravenous immunoglobu-
lins (n = 20), steroids (n = 17) or both (n = 15), with typically only 
partial recovery over time. Follow-up time ranged from 0.5 to 12 
months. Two patients, who both showed EV-D68 in the CSF, died. 
One was a 55-year-old immunocompromised woman, who died of 
respiratory failure. The second was a 3.5-year-old child, who died 
of severe ventilation acquired pneumonia with septic shock.
Epidemiology and Diagnostics
From March to October 2016, 21,875 EV tests were reported 
by 16 European laboratories, as shown in the Table (Supplemental 
Digital Content 4, http://links.lww.com/INF/D272). This table does 
not contain the data from EV-D68 AFM cases that were reported by 
clinicians without epidemiologic data from the diagnostic labora-
tory, so it has only a partial overlap with Table 1. Of the 21,875 
EV tests reported on all clinical specimens, 2111 were EV posi-
tive (10%; excluding those EV-positive samples for which no 
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Demographics   
  Median age (yr) 29 4 (1.6–55)
  Male gender 29 15 (52%)
Prodromal symptoms   
  Fever 26 24 (92%)
  Respiratory symptoms 29 26 (90%)
  Gastrointestinal symptoms 29 7 (24%)
  Median days of fever until onset of weakness 22 2 (0–8)
Neurologic symptoms   
  Cranial nerves affected 28 17 (60%)
   Facial nerve palsy  8 (29%)
   Dysphagia  4 (14%)
   Bulbar symptoms  9 (32%)
   Eye movement disorders  5 (18%)
  Ventilatory support needed 29 19 (66%)
  Limb weakness 29 29 (100%)
   1 limb  3 (10%)
   2 limbs  8 (28%)
   3 limbs  0 (0%)
   4 limbs  16 (55%)
   Limbs not specified  2 (7%)
  Hyporeflexia/areflexia 22 20 (87%)
Other symptoms 29 Autonomic dysfunction, n = 3
  Acute respiratory distress syndrome, n = 1
  Generalized convulsions, n = 1
  Limb ataxia, n = 1
  Limb pain, n = 4
  Neurogenic bladder dysfunction, n = 1
  Paresthesia, n = 2
  Pneumonia, n = 4
  Transient myocardial dysfunction, n = 1
CSF analysis   
  Pleocytosis (CSF cell count >5 leukocytes/µL) 22 20 (91%)
  Median CSF cell count (leukocytes/µL) 20 79 (3–416)
  Median CSF protein level (g/L) 17 0.38 (0.21–1.6)
MRI abnormalities   
  MRI: Hyperintensity central cord 25 23 (92%)
   Location (if specified) 20 Cervical, n = 10
  Cervical/thoracic, n = 6
  Thoracic/lumbar, n = 1
  Entire spinal cord, n = 3
  MRI brain: Hyperintensity dorsal pons/medulla 25 17 (68%)
  Other MRI abnormalities 6 Enhancing roots, n = 4
  Meningeal enhancement, n = 1
  Hyperintensity dentate nuclei, dorsal  
medulla, n = 1
Electromyography 11  
  Low motor amplitudes  10 (91%)
  Reduced conduction velocities  1 (9%)
  Spontaneous muscle fiber activity  5 (45%)
Treatment 24  
  Intravenous immunoglobulin  20 (83%)
  Intravenous steroids  17 (71%)
  Plasmapheresis  5 (21%)
  Other  Fluoxetine, n = 1; rituximab, n = 1
Follow-up 28  
  Full recovery  3 (11%)
  Partial recovery  21 (75%)
  No recovery  2 (7%)
  Death  2 (7%)
  Median follow-up time (mo) 24 4 (0.5–12)
Virology   
  EV-D68 positive in:   
   Any sample 29 29 (100%)
    CSF 25 2 (8%)
    Respiratory sample 28 27 (96%)
    Fecal sample 22 8 (36%)
Two patients were diagnosed in December 2015. Sixteen cases were previously reported in separate publications.10,11,13–18
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denominator was given). Of the total number of 2381 EV-positive 
samples, 416 were EV-D68 (17%). Taking a closer look at respira-
tory samples, 10,226 EV tests were performed, with 987 (10%) EV-
positive samples. Of the total amount of 1067 EV-positive samples 
in respiratory specimens, 414 were EV-D68 positive (39%). Only 1 
of 558 EV-positive CSF samples (0.18%) and 1 of 711 EV-positive 
feces samples (0.14%) was positive for EV-D68 (data not shown in 
the table).
Sequence data of the viral protein 1 region were available 
for 6 of 29 AFM patients, and together with many other EV-D68 
strains of 2014 and 2016, these were used for sequence analysis. 
The Figure (Supplemental Digital Content 5, http://links.lww.com/
INF/D273) shows the dominance of the B3 clade in 2016, irrespec-
tive of respiratory or neurologic symptoms.
Notification Regulations
The following information was obtained regarding notifica-
tion regulations: AFP/AFM is a reportable disease in all European 
countries within the scope of polio eradication. Only in Norway, 
also non-polio AFP/AFM cases are notifiable and the requirement 
of a respiratory sample for testing was added after the EV-D68 
outbreak in 2014. In Germany and France, non-polio AFP/AFM is 
voluntarily reported. In Norway, Sweden, Ireland, Italy, France and 
Slovenia, (entero-) (viral) meningitis/encephalitis is reportable. In 
Denmark, EV meningitis and paralysis are reportable and recently 
the required specimens for testing were expanded with a respiratory 
sample.19 For the remaining countries, no clear regulations exist for 
non-polio AFP/AFM cases.
DISCUSSION
The association between EV-D68 and AFM has become 
clear since 2014, although causality was not yet proven.4,6,20 The 
recent publication of a mouse model,21 in which mice that had 
been inoculated with EV-D68 developed symptoms of myelitis, 
added important evidence supporting causality. Furthermore, using 
the Bradford-Hill criteria, 2 groups evaluated both the epidemio-
logic and biologic evidence linking EV-D68 to AFM.22,23 Several 
case reports and small case series have been published from the 
United States, Canada, South America, Australia, Asia and Europe, 
describing patients with EV-D68–related AFM.7,8,10,11,13–18,24–30 In 
this article, we presented the first comprehensive EV-D68 AFM 
case series and an epidemiologic overview for Europe in 2016.
Clinical Manifestations and Treatment
In children, the median age of 3.8 years at onset of AFM 
was in line with the median age in a Japanese EV-D68–related 
AFM upsurge in 2015 (4.4 years30), but somewhat lower than the 
median age of those affected in 2014 in the United States (7.1 
years4). If this is a true difference, it would be interesting to inves-
tigate if lower serologic protection rates in the 4-year-olds in 2016 
could have caused this shift. We included the 3 adult cases in our 
series to point out that EV-D68–related AFM is not restricted to 
childhood age.
The clinical presentation of the affected patients in Europe 
2016 resembled that of patients from other parts of the world 
regarding prodromal symptoms and neurologic manifestations, 
with asymmetric flaccid limb weakness, sometimes accompanied 
FIGURE 1. Typical magnetic resonance imaging findings in patients with enterovirus-D68–associated acute flaccid myelitis. 
Magnetic resonance images of 2 cases (case a: A–C; case b: D–E), dating from the first week after the start of neurologic 
symptoms, showing typical imaging features of AFM. A + D, Transversal T2-weighted images of the brain show a slight 
hyperintensity (arrow) in the dorsal pons. B + E, Sagittal T2-weighted images show hyperintensity (arrow) of the central 
gray matter in the cervical and thoracic regions in both patients. C, A sagittal T1-weighted image with gadolinium shows 
enhancement (arrows) of the caudal roots.
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by pain, cranial nerve deficits and bulbar symptoms.26 It may be 
difficult to distinguish AFM clinically from other neurologic dis-
eases, such as Guillain–Barre syndrome, acute transverse myelitis, 
Miller Fisher syndrome or acute disseminated encephalomyelitis. 
Additionally, mild cases can be easily missed. The case definition 
provides descriptions of specific MRI lesions along the spinal cord. 
Additionally, in the literature, lesions in the grey matter of the ante-
rior horn and in the brainstem are described, as well as contrast 
enhancement of nerve roots.31 When MRI is not performed or these 
specific MRI lesions are not (yet) visible, patients may meet the cri-
teria of a probable case when they show a mild CSF pleocytosis,5,26 
as did 1 of our patients. Two patients strictly did not fulfill the cri-
teria of the case definition, as MRI results and CSF analyses were 
lacking. They were nevertheless included in this study, based on the 
clinical picture of AFM with respiratory insufficiency and/or bul-
bar symptoms, and the detection of EV-D68 in respiratory samples.
If feasible in the young child, EMG findings can be of great 
value in supporting the diagnosis of AFM. Thus far, children with 
EV-D68–associated AFM generally showed low amplitude com-
pound muscle action potentials, most often with normal conduction 
velocity, without signs of sensory nerve conduction abnormalities. 
In a later stage of disease, spontaneous muscle fiber activity can be 
found in the affected muscles.26,32
Although an attempt was made to capture the features of 
EV-D68–related AFM in a case definition, it should be emphasized 
that EV-D68 is not the only virus that can cause AFM. For example, 
West-Nile virus and other EVs, such as EV-A71, should be consid-
ered as causative agents. Neither is AFM the only neurologic dis-
order that is associated with EV-D68 infection; EV-D68 has been 
found in patients with rhombencephalitis24 and, in this cases series, 
1 child from France was submitted with a Guillain–Barre syndrome 
and a concurrent EV-D68 infection (data not shown).
Various treatment regimens were prescribed in this case 
series. It is unfortunately not possible to deduce any positive or 
negative effects from these data. Similarly, in other series, no thera-
peutic intervention seemed to have significantly improved outcome. 
However, with a mouse model, Hixon et al21 showed that EV-D68 
immune-sera protected mice from development of paralysis and 
death when administered before viral challenge. Furthermore, recent 
data using this mouse model showed a favorable effect of intravenous 
immunoglobulin administered after infection as well; high-dose cor-
ticosteroids, however, had a negative effect on motor function and 
mortality.33 Because of these findings, treatment protocols with corti-
costeroids as a first-line treatment may be subject to discussion.
In the literature, full neurologic rehabilitation has occurred 
only in a minority of patients after a 12- to 18-month period of 
follow-up, although MRI lesions may disappear.34,35 The 2016 
EV-D68 AFM Working Group aims at a standardized follow-up of 
the European patients beyond 12 months after the onset of illness, 
to get more insight in the natural course of the disease and to fur-
ther improve education of patients and parents on the prognosis of 
EV-D68–related AFM.
In this series, the 2 patients who showed EV-D68 in the CSF 
did not survive. This may imply more severe disease, but larger 
studies are needed to evaluate this.
Epidemiology and Diagnostics
Our data showed a wide range of both EV positivity rates 
and EV-D68 positivity rates between the laboratories. This is likely 
explained by differences in non-polio EV-surveillance strategies 
and testing and typing algorithms in Europe, as mapped out by 
Harvala et al.36 A way to overcome these differences would be the 
intensification of non-polio EV-surveillance, such as initiated in 
Denmark and by the European non-polio EV network.19,37
Standard EV diagnostics, as well as poliovirus surveillance, 
generally relies on testing in feces, as poliovirus and the majority of 
other EV serotypes can indeed be detected in fecal samples. How-
ever, our epidemiologic data show that 99% of EV-D68–positive 
samples were respiratory specimens. This underlines that EV-D68 
has a predominant respiratory tropism and respiratory specimens 
are required for identification of the virus.9,26,35 The near absence of 
EV-D68 in fecal samples is in line with a previous study.38 However, 
in our case series, EV-D68 was more frequently detected in feces and 
CSF than was expected based on our epidemiologic data. This differ-
ence likely reflects the widespread occurrence of EV-D68 respiratory 
disease, with the virus being present in respiratory specimens, and 
the rarity of EV-D68–related AFM, with the virus potentially pre-
sent in multiple compartments, plus a more thorough microbiologic 
investigation in AFM patients because of disease severity.
Recently, the World Health Organization and the Pan Ameri-
can Health Organization have released an epidemiologic alert to 
include testing for EV-D68 on respiratory samples in cases of AFP/
AFM, both for case management and for surveillance purposes.39 It 
is important to note that not all respiratory PCR panels include EV 
as a target. Second, not all molecular tests that target EVs are able 
to detect EV-D68 or distinguish EV-D68 from rhinoviruses. Com-
munication between clinicians and virologists is therefore essential 
to optimize diagnostics.
Sequence analysis showed that most of the EV-D68 strains in 
2014 clustered with clades A1, A2, B1 and B2.3,40 In 2016, however, 
nearly all strains belonged to subclade B3 in Europe as well as in the 
United States.40 The clinical importance of this shift is yet unclear.
This study reveals that crucial information is often not 
(timely) available, among others by a lack of non-polio AFP/AFM 
notification regulations, and therefore the overview is by no means 
complete. By activating the 2016 EV-D68 AFM Working Group 
network, we were able to identify 29 EV-D68–related AFM cases 
in Europe in 2016, but these probably represent only the tip of the 
iceberg. All cases were reported by countries that had also joined in 
the 2014 initiative. Clearly, these countries were already interested 
in EV-associated diseases and were therefore more prompted to 
identify cases when confronted with paralyzed patients. Additional 
AFM cases that may have been due to EV-D68 but did not have 
etiology confirmed because of late or absent sampling and testing, 
likely have been missed.
As EV-D68 has shown a cyclic pattern since 2010,11,29,41 it is 
conceivable that the virus might reappear in the very near future. 
As no major changes have occurred in making AFM reportable in 
Europe, a new outbreak may go largely undetected by the health 
authorities. In the short term, we might benefit most from an e-mail 
alert system, by which clinicians and laboratories inform each other 
on the start of the EV season, the upsurge of rare types and on spe-
cial EV-associated syndromes, such as AFM.
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